We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?
Read MoreHide Full Article
Key Takeaways
ABBV is counting on Skyrizi and Rinvoq to drive growth post-Humira as Q2 results near.
Skyrizi and Rinvoq saw broad uptake across IBD and new indications like GCA and atopic dermatitis.
ABBV expects combined Q2 sales of $6 billion from Skyrizi and Rinvoq to support 2025 growth.
AbbVie (ABBV - Free Report) has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer immunology medicines, Skyrizi and Rinvoq. Investors will be most keen to know the sales numbers of these two drugs when the company reports second-quarter results on July 31.
AbbVie successfully launched Skyrizi and Rinvoq across Humira's major indications and a distinct new indication, atopic dermatitis. Both drugs showed strong performance across all approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes two conditions — ulcerative colitis (UC) and Crohn’s disease (CD). In April, AbbVie secured label expansion for Rinvoq across both the United States and Europe in the giant cell arteritis (GCA) indication, which is also likely to have contributed to sales growth during the second quarter.
Driven by the robust performance of these two drugs, AbbVie expects to return to growth in 2025, despite it just being the second year following the U.S. Humira LOE. Our model estimates for Skyrizi and Rinvoq sales are pegged at $4 billion and $2 billion, respectively, for the to-be-reported quarter.
In addition to immunology, AbbVie has been expanding its presence in oncology and neuroscience. In recent years, ABBV has added Epkinly, Elahere and most recently, Emrelis, bringing its total oncology therapies to five. Growth in its neuroscience segment has also been supported by increasing uptake of its migraine drugs, Ubrelvy and Qulipta.
ABBV’s Peers in the Immunology Space
The targeted market is highly competitive. A key player in this field is Johnson & Johnson (JNJ - Free Report) , which already markets two blockbuster drugs — Stelara and Tremfya. Both of these J&J medications are approved for multiple immunology indications, including UC and CD. Since Stelara lost U.S. patent exclusivity earlier this year, J&J has shifted its focus to Tremfya to maintain its market position.
Another pharma giant expanding its presence in immunology is Eli Lilly (LLY - Free Report) , following the FDA approval of Omvoh for the UC indication in late 2023. Omvoh marked Lilly’s first immunology drug approved for a type of IBD in the United States, playing a key role in expanding its immunology portfolio. The Lilly drug received FDA approval for the CD indication in January.
ABBV’s Price Performance, Valuation and Estimates
Shares of AbbVie have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is not very cheap. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 14.21 times forward earnings, a tad lower than its industry’s average of 15.01. The stock is cheaper than some other large drugmakers, such as Eli Lilly and Novo Nordisk, but is priced much higher than most other large drugmakers. The stock is also trading above its five-year mean of 12.48.
Image Source: Zacks Investment Research
The bottom-line estimate for 2025 has remained consistent at $12.28, while that for 2026 has increased from $14.05 to $14.06 over the past 30 days.
Image: Shutterstock
How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?
Key Takeaways
AbbVie (ABBV - Free Report) has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer immunology medicines, Skyrizi and Rinvoq. Investors will be most keen to know the sales numbers of these two drugs when the company reports second-quarter results on July 31.
AbbVie successfully launched Skyrizi and Rinvoq across Humira's major indications and a distinct new indication, atopic dermatitis. Both drugs showed strong performance across all approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes two conditions — ulcerative colitis (UC) and Crohn’s disease (CD). In April, AbbVie secured label expansion for Rinvoq across both the United States and Europe in the giant cell arteritis (GCA) indication, which is also likely to have contributed to sales growth during the second quarter.
Driven by the robust performance of these two drugs, AbbVie expects to return to growth in 2025, despite it just being the second year following the U.S. Humira LOE. Our model estimates for Skyrizi and Rinvoq sales are pegged at $4 billion and $2 billion, respectively, for the to-be-reported quarter.
In addition to immunology, AbbVie has been expanding its presence in oncology and neuroscience. In recent years, ABBV has added Epkinly, Elahere and most recently, Emrelis, bringing its total oncology therapies to five. Growth in its neuroscience segment has also been supported by increasing uptake of its migraine drugs, Ubrelvy and Qulipta.
ABBV’s Peers in the Immunology Space
The targeted market is highly competitive. A key player in this field is Johnson & Johnson (JNJ - Free Report) , which already markets two blockbuster drugs — Stelara and Tremfya. Both of these J&J medications are approved for multiple immunology indications, including UC and CD. Since Stelara lost U.S. patent exclusivity earlier this year, J&J has shifted its focus to Tremfya to maintain its market position.
Another pharma giant expanding its presence in immunology is Eli Lilly (LLY - Free Report) , following the FDA approval of Omvoh for the UC indication in late 2023. Omvoh marked Lilly’s first immunology drug approved for a type of IBD in the United States, playing a key role in expanding its immunology portfolio. The Lilly drug received FDA approval for the CD indication in January.
ABBV’s Price Performance, Valuation and Estimates
Shares of AbbVie have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is not very cheap. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 14.21 times forward earnings, a tad lower than its industry’s average of 15.01. The stock is cheaper than some other large drugmakers, such as Eli Lilly and Novo Nordisk, but is priced much higher than most other large drugmakers. The stock is also trading above its five-year mean of 12.48.
Image Source: Zacks Investment Research
The bottom-line estimate for 2025 has remained consistent at $12.28, while that for 2026 has increased from $14.05 to $14.06 over the past 30 days.
Image Source: Zacks Investment Research
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.